MedTrace Logo

Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis

NCT02123316 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-03-31

No results posted yet for this study

Summary

To evaluate the efficacy of an extract of Dermatophagoides pteronyssinus versus placebo in the treatment of local allergic rhinitis. The primary efficacy endpoint is the reduction in symptom scores and medication use in the active group compared to placebo.

The influence of treatment in "in vitro" and "in vivo" objective parameters was also assessed.

Conditions

  • Local Allergic Rhinitis

Interventions

BIOLOGICAL

Pangramin Plus D. pteronyssinus

Subcutaneous immunotherapy with Dermatophagoides pteronyssinus

BIOLOGICAL

Placebo

Placebo for subcutaneous injection

Sponsors & Collaborators

  • Miguel Blanca Gomez

    lead OTHER

Principal Investigators

  • Miguel Blanca, MD, PhD · Allergy Unit, Regional University Hospital of Malaga, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02123316 on ClinicalTrials.gov